查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1649516

荷爾蒙避孕藥市場：預測（2025-2030）

Hormonal Contraceptives Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 141 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計荷爾蒙避孕藥市場規模將從 2025 年的 78.36 億美元成長到 2030 年的 101.84 億美元，預測期內的複合年成長率為 5.38%。

荷爾蒙避孕藥是使用合成荷爾蒙透過抑制排卵、增稠子宮頸黏液和改變子宮內膜來防止懷孕的避孕藥。由於對計劃生育和生殖健康諮詢的需求不斷增加，預計全球荷爾蒙避孕藥的收益成長將會加速。這一趨勢將荷爾蒙避孕定位為主要的計劃生育解決方案，促進婦女健康和賦權，增加獲得避孕的保護條例和政府舉措，並解決性行為感染傳染病（STD）的發病率。此外，各大公司加大對新型避孕設備的開發投入、政府推出的各種旨在擴大避孕設備市場的舉措以及醫療相關人員認知的不斷提高都是推動市場成長的主要因素。隨著女性對避孕方法的了解越來越多，預計由意識主導的市場成長將從歷史最低水準飆升。

荷爾蒙避孕藥市場促進因素

  • 採用有效的荷爾蒙避孕藥：新型有效產品的推出推動了荷爾蒙避孕藥的需求。幾家主要企業正在投資先進的避孕技術。這種轉變在美國等已開發國家尤其明顯，NuvaRing 等產品在這些國家越來越受歡迎。這種避孕環具有與傳統避孕藥相當的功效，但使用方便，只需每三週更換一次。

主要區域趨勢

  • 北美有望領先：預計預測期內北美地區的荷爾蒙避孕藥市場將顯著成長。這種成長可歸因於現代化的醫療保健基礎設施、高度的計劃生育意識以及廣泛的避孕選擇。美國和加拿大憑藉其在醫療保健系統的強勁投資、廣泛的研發機會以及在健康相關產品上的高消費者支出佔據了市場的大部分佔有率。此外，政府計畫和綜合健康保險增加了獲得荷爾蒙避孕的機會。

強大的醫療保健提供者網路和避孕技術的不斷進步進一步支持了其在推動北美荷爾蒙避孕市場成長方面的領導地位。

為什麼要購買這份報告？

  • 深刻分析：獲得深入的市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔，涵蓋主要地區和新興地區。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中開闢新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問公司、中小企業和大型企業都有益且具有成本效益。

它有什麼用途？

產業與市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

  • 2022 年至 2030 年的實際資料和預測
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭定位、策略與市場佔有率分析
  • 細分和區域分析，包括收益成長和預測國家
  • 公司概況（策略、產品、財務、主要發展等）

荷爾蒙避孕藥市場區隔如下：

依產品類型

  • 口服避孕藥
  • 注射
  • 皮膚貼劑
  • 子宮內避孕器 (IUD)
  • 避孕環
  • 事後緊急避孕藥

依激素類型

  • 僅含黃體素的避孕藥
  • 合併荷爾蒙避孕藥

按通路

  • 醫院
  • 零售
  • 線上

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 西班牙
  • 義大利
  • 其他
  • 中東和非洲
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 其他
  • 亞太地區
  • 日本
  • 中國
  • 印度
  • 韓國
  • 印尼
  • 泰國
  • 台灣
  • 其他

目錄

第 1 章 簡介

  • 市場概況
  • 市場定義
  • 研究範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 研究過程

第3章執行摘要

  • 主要發現

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

5. 荷爾蒙避孕藥市場（依產品類型）

  • 介紹
  • 口服避孕藥
  • 注射避孕藥
  • 皮膚貼劑
  • 子宮內避孕器 (IUD)
  • 避孕環
  • 事後緊急避孕藥

6. 荷爾蒙避孕市場（依荷爾蒙類型分類）

  • 介紹
  • 僅含黃體素的避孕藥
  • 合併荷爾蒙避孕藥

7. 荷爾蒙避孕藥市場（依分銷管道）

  • 介紹
  • 醫院
  • 零售
  • 線上

8. 荷爾蒙避孕藥市場（按地區）

  • 介紹
  • 北美洲
    • 依產品類型
    • 依激素類型
    • 按分銷管道
    • 按國家
  • 南美洲
    • 依產品類型
    • 依激素類型
    • 按分銷管道
    • 按國家
  • 歐洲
    • 依產品類型
    • 依激素類型
    • 按分銷管道
    • 按國家
  • 中東和非洲
    • 依產品類型
    • 依激素類型
    • 按分銷管道
    • 按國家
  • 亞太地區
    • 依產品類型
    • 依激素類型
    • 按分銷管道
    • 按國家

第9章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭儀錶板

第10章 公司簡介

  • Bayer AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Limited
  • Mylan NV
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Church & Dwight, Co., Inc.
  • Ansell LTD.
  • Mayer Laboratories
  • The Female Health Company
  • Allergan plc
  • Afaxys, Inc.
  • Agile Therapeutics
  • Novartis AG
  • Prega International
簡介目錄
Product Code: KSI061617281

The hormonal contraceptives market is projected to grow at a CAGR of 5.38% over the forecast period, increasing from US$7.836 billion in 2025 to US$10.184 billion by 2030.

Hormonal contraception refers to contraceptive pills that utilize synthetic hormones to prevent pregnancy by inhibiting ovulation, thickening cervical mucus, and altering the uterine lining. The growth of global revenues in hormonal contraception is expected to accelerate due to the rising demand for family planning and reproductive health counseling. This trend positions hormonal contraception as a leading solution for family planning, fostering women's health and empowerment, increasing protective regulations and government initiatives for contraceptive access, and addressing the incidence of sexually transmitted diseases (STDs). These factors collectively create pressure to adhere to preventive measures.Additionally, increased investments from major players in developing new contraceptive devices, various government initiatives aimed at expanding the contraceptive market, and heightened awareness among medical professionals are significant drivers of market growth. As women become more informed about their options for preventing pregnancy, awareness-driven market growth is anticipated to rise rapidly from a previously low base.

Drivers of the Hormonal Contraceptives Market

  • Introduction of Effective Hormonal Contraceptives: The demand for hormonal contraceptives is being driven by the introduction of novel and effective products. Several leading companies are investing in advanced technologies for contraceptive solutions. This shift has been particularly notable in developed countries like the United States, where products such as the NuvaRing have gained popularity. The vaginal ring offers comparable efficacy to traditional contraceptive pills but is user-friendly and only requires replacement every three weeks.

Key Geographical Trends

  • North America Expected to Lead: The North American region is projected to experience significant growth in the hormonal contraceptives market during the forecast period. This growth can be attributed to a modern healthcare infrastructure, high awareness of family planning, and a wide range of available contraceptive options. The U.S. and Canada hold substantial shares of the market due to robust investments in healthcare systems, extensive research and development opportunities, and considerable consumer spending on health-related products. Furthermore, government programs and comprehensive health insurance coverage enhance access to hormonal contraceptives.

The strong network of healthcare institutions and ongoing advancements in contraceptive technology further support North America's leadership in promoting growth within the hormonal contraception market.________________________________________

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Hormonal contraceptives Market has been segmented as following:

By Product Type

  • Oral Contraceptives
  • Injectable Contraceptive
  • Skin Patches
  • Intrauterine Devices (IUDs)
  • Vaginal Rings
  • Emergency Contraceptive Pills

By Hormone Type

  • Progestin-Only Contraceptives
  • Combined Hormonal Contraceptives

By Distribution Channel

  • Hospital
  • Retail
  • Online

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific Region
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. HORMONAL CONTRACEPTIVES MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Oral Contraceptives
  • 5.3. Injectable Contraceptive
  • 5.4. Skin Patches
  • 5.5. Intrauterine Devices (IUDs)
  • 5.6. Vaginal Rings
  • 5.7. Emergency Contraceptive Pills

6. HORMONAL CONTRACEPTIVES MARKET BY HORMONE TYPE

  • 6.1. Introduction
  • 6.2. Progestin-Only Contraceptives
  • 6.3. Combined Hormonal Contraceptives

7. HORMONAL CONTRACEPTIVES MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital
  • 7.3. Retail
  • 7.4. Online

8. HORMONAL CONTRACEPTIVES MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product Type
    • 8.2.2. By Hormone Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Product Type
    • 8.3.2. By Hormone Type
    • 8.3.3. By Distribution Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Product Type
    • 8.4.2. By Hormone Type
    • 8.4.3. By Distribution Channel
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. France
      • 8.4.4.3. Germany
      • 8.4.4.4. Spain
      • 8.4.4.5. Italy
      • 8.4.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Product Type
    • 8.5.2. By Hormone Type
    • 8.5.3. By Distribution Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Israel
      • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Product Type
    • 8.6.2. By Hormone Type
    • 8.6.3. By Distribution Channel
    • 8.6.4. By Country
      • 8.6.4.1. Japan
      • 8.6.4.2. China
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Thailand
      • 8.6.4.7. Taiwan
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Bayer AG
  • 10.2. Pfizer, Inc.
  • 10.3. Teva Pharmaceutical Industries Limited
  • 10.4. Mylan N.V.
  • 10.5. Johnson & Johnson
  • 10.6. Merck & Co., Inc.
  • 10.7. Church & Dwight, Co., Inc.
  • 10.8. Ansell LTD.
  • 10.9. Mayer Laboratories
  • 10.10. The Female Health Company
  • 10.11. Allergan plc
  • 10.12. Afaxys, Inc.
  • 10.13. Agile Therapeutics
  • 10.14. Novartis AG
  • 10.15. Prega International